By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Merrimack Pharmaceuticals Inc. 

101 Binney Street

Cambridge  Massachusetts  02142  U.S.A.
Phone: 617-441-1000 Fax: 617-491-1386


Start Up


Dyax  Antibody phage display

Company News
Merrimack (MACK) And Baxalta (BXLT) Announce Publication Of The ONIVYDE (irinotecan liposome injection) NAPOLI-1 Study In The Lancet 11/23/2015 6:39:29 AM
Merrimack (MACK) Reports Third Quarter 2015 Financial Results 11/10/2015 8:06:04 AM
Merrimack (MACK) To Present Research On Multiple Programs At The 2015 AACR-National Cancer Institute-EORTC International Conference On Molecular Targets And Cancer Therapeutics 11/4/2015 7:20:07 AM
Merrimack (MACK) Announces Timing Of Third Quarter 2015 Investor Conference Call 11/2/2015 7:17:45 AM
Merrimack (MACK) And Baxalta (BXLT) Announce Enrollment Of First Patient In Phase 2 Study Of ONIVYDE (irinotecan Liposome Injection) In Previously Untreated Front-Line Metastatic Pancreatic Cancer 10/27/2015 7:59:41 AM
Merrimack (MACK) Announces U.S. FDA Approval Of ONIVYDE (Irinotecan Liposome Injection) For The Treatment Of Patients With Metastatic Pancreatic Cancer 10/23/2015 7:34:20 AM
Merrimack (MACK) Debuts New Website 9/25/2015 12:08:19 PM
Merrimack (MACK) Ramps Up Sales Force in Anticipation of Regulatory Approval of Pancreatic Cancer Drug 9/9/2015 6:40:46 AM
Merrimack (MACK) Reports Second Quarter 2015 Financial Results 8/11/2015 7:54:46 AM
Merrimack (MACK) Names Dr. Yasir Al-Wakeel As Chief Financial Officer And Head Of Corporate Development 8/6/2015 7:35:41 AM